Related Experiment Videos
Unexpected mortality reduction with abciximab for in-stent restenosis
D Mukherjee1, J P Reginelli, D J Moliterno
1Department of Cardiology, Desk F-25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
The Journal of Invasive Cardiology
|November 4, 2000
Summary
Adjunctive abciximab in percutaneous coronary intervention (PCI) for in-stent restenosis may lower risks. This study found lower myocardial infarction and mortality rates in patients receiving abciximab during PCI for in-stent restenosis.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- In-stent restenosis treatment is generally low-risk.
- The benefit of abciximab in this population is uncertain.
Purpose of the Study:
- To evaluate the effect of adjunctive abciximab during percutaneous coronary intervention (PCI) for in-stent restenosis.
- To assess if abciximab improves outcomes in patients with in-stent restenosis.
Main Methods:
- Retrospective analysis of 284 patients undergoing PCI for in-stent restenosis.
- Comparison between 79 patients receiving abciximab and 205 patients not receiving abciximab.
- Exclusion of patients treated with directional atherectomy, laser, or brachytherapy.
Main Results:
- The abciximab group had significantly lower rates of myocardial infarction (2.5% vs 5.3%) and mortality (1.2% vs 5.8%) at 1-year follow-up.
- No significant difference in revascularization rates was observed between the groups.
- The abciximab group had a higher prevalence of diabetes, hypertension, and elevated cholesterol.
Conclusions:
- Adjunctive abciximab use during PCI for in-stent restenosis was associated with reduced mortality and myocardial infarction.
- These findings suggest a potential benefit of abciximab in this patient group.
- Further prospective studies are warranted to confirm these results.